Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strides Pharma Science's quarterly market cap
increased
from Sep. 2025 (₹76,020 Mil) to Dec. 2025 (₹83,172 Mil) and
increased
from Dec. 2025 (₹83,172 Mil) to Mar. 2026 (₹86,435 Mil).
Strides Pharma Science's annual market cap
increased
from Mar. 2024 (₹32,898 Mil) to Mar. 2025 (₹61,657 Mil) and
increased
from Mar. 2025 (₹61,657 Mil) to Mar. 2026 (₹86,435 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Strides Pharma Science's Enterprise Value for Today is ₹111,551 Mil.
Strides Pharma Science (BOM:532531) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Market Cap distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Strides Pharma Science's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strides Pharma Science (BOM:532531) has a Market Cap of ₹97,657 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Strides Pharma Science and its competitors. According to the industry distribution chart, Strides Pharma Science ranks #256 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 25%.
Is Strides Pharma Science's Market Cap too high?
Strides Pharma Science's current Market Cap is ₹97,657 Mil. Based on the distribution chart, Strides Pharma Science ranks #256 out of 1022 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Strides Pharma Science has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #256 out of 1022 companies for Market Cap. This places Strides Pharma Science in the top 25% of its industry — outperforming the majority of peers. The industry median Market Cap is 222.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 222.28, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median Market Cap is 222.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current Market Cap is ₹97,657 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (BOM:532531) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹781.95, compared to a current price of ₹1,057.95 — trading 35.3% above its estimated fair value. The current Market Cap is ₹97,657 Mil. Strides Pharma Science's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Strides Pharma Science (BOM:532531), the current Market Cap is ₹97,657 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (BOM:532531) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,057.95 is trading 35.3% above its estimated GF Value™ of ₹781.95.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for BOM:532531:
Market Cap: ₹97,657 Mil
GF Value™: ₹781.95 vs. price of ₹1,057.95 (35.3% above fair value)
No single metric tells the full story. See the BOM:532531 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
61GF Score
Get the complete analysis for BOM:532531
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532531 has been successfully added to your 
